- « Previous Releases | Next Releases »
RESEARCH TRIANGLE PARK, N.C., Oct 25, 2010 (BUSINESS WIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Stuart Grant, Senior Vice President and Chief Financial Officer of BioCryst, plans to provide a corporate summary and update regarding its clinical programs at the 21st Annual Oppenheimer Healthcare Conference in New York City on Tuesday, November 2, 2010 at 9:40 a.m. Eastern Time.
Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at www.biocryst.com.
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at www.biocryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
SOURCE: BioCryst Pharmaceuticals, Inc.
Copyright Business Wire 2010